Updates in the FDA’s Regulation of Digital Health Technologies

Knobbe Martens
Contact

Knobbe Martens

The FDA issued a warning letter to Abiomed, for failing to seek approval for its Impella Connect System software before putting it on the market. The Impella Connect System software is designed to work with the company’s Automated Impella Controller (AIC), which is part of a medical device system that provides temporary ventricular support to help a patient’s heart to pump blood in a critical care setting.

Abiomed attempted to argue that functions of the Impella Connect System were non-device clinical decision support (CDS) software functions or non-device medical device data systems, but the FDA disagreed. The FDA asserted that the software component, by providing “time-critical alarms and patient-specific medical information intended to trigger potential clinical intervention to assure patient safety,” qualifies as a medical device requiring premarket authorization. This warning letter highlights the FDA’s intention to enforce regulatory oversight of medical device data systems that go beyond basic electronic data transfer and storage functions. The development is significant for companies involved in wearable medical devices and patient monitoring technologies.

The warning letter is just one example of the FDA’s broader ongoing efforts to adapt to the challenges posed by digital health technologies including clinical decision support software, AI-enabled medical devices, digital therapeutics, wearables, remote patient monitoring, and more. Impella Connect® Instructions for Use | HeartRecovery.com

 

Notably, the FDA recently announced that it is establishing a Digital Health Advisory Committee. The committee, set to be fully operational in 2024, will consist of experts from various disciplines who will advise FDA leaders on digital health-related matters, with the goal of ensuring the safety and effectiveness of emerging technologies without stifling innovation. It will be accepting applications until December 11th, 2023.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Knobbe Martens

Written by:

Knobbe Martens
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Knobbe Martens on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide